theophylline has been researched along with Smoking Cessation in 26 studies
Smoking Cessation: Discontinuing the habit of SMOKING.
| Excerpt | Relevance | Reference |
|---|---|---|
| " From the reports of suspected adverse reactions received by the Netherlands Pharmacovigilance Foundation, it appears that more than half the cases concerned patients at risk of developing smoking-related diseases." | 6.41 | [Uneasiness about the safety of bupropion as an aid to smoking cessation unjustified ]. ( Chavannes, NH; de Graaf, L; van Grootheest, AC; van Schayck, CP; Wagena, EJ, 2001) |
| "The period prevalence of patients at risk of a potentially highly significant medication-smoking cessation interaction was 23/48 (48%), 66/256 (26%) and 1/16 (6%) amongst smokers prescribed clozapine, olanzapine or theophylline, respectively." | 3.91 | Prevalence and recognition of highly significant medication-smoking cessation interactions in a smoke-free hospital. ( Chui, CY; George, J; Taylor, SE; Thomas, D, 2019) |
| "Smoking cessation is the only known causative treatment option." | 2.43 | [Pharmacological treatment of COPD and future of anti-inflammatory therapy]. ( Bitter-Suermann, S; Kanniess, F; Magnussen, H; Watz, H, 2006) |
| "The treatment of chronic obstructive pulmonary disease (COPD) has improved substantially over recent years, and is increasingly based on evidence from prospective studies." | 2.43 | [Stage appropriate therapy for COPD]. ( Hamm, H, 2006) |
| "Smoking cessation is the only intervention that has proved effective." | 2.43 | Pharmacological treatment of chronic obstructive pulmonary disease. ( Montuschi, P, 2006) |
| "Chronic obstructive pulmonary disease (COPD) is a major health problem across the world and its medical, societal and economic impacts continue to grow." | 2.42 | Approaches to slowing the progression of COPD. ( Altose, MD, 2003) |
| "The care of patients with chronic obstructive pulmonary disease (COPD) has changed radically over the past 2 decades, and novel therapies can not only improve the health status of patients with COPD but also modify its natural course." | 2.42 | Contemporary management of chronic obstructive pulmonary disease: scientific review. ( Anthonisen, NR; Man, SF; McAlister, FA; Sin, DD, 2003) |
| "Smoking cessation is a basic standing point for management of COPD." | 2.42 | [Management of patients with stable COPD]. ( Toyoshima, H; Yoshida, M, 2003) |
| "Theophylline has weak antiinflammatory effects." | 2.42 | [New drug therapy of chronic obstructive pulmonary disease]. ( Kino, H, 2003) |
| " From the reports of suspected adverse reactions received by the Netherlands Pharmacovigilance Foundation, it appears that more than half the cases concerned patients at risk of developing smoking-related diseases." | 2.41 | [Uneasiness about the safety of bupropion as an aid to smoking cessation unjustified ]. ( Chavannes, NH; de Graaf, L; van Grootheest, AC; van Schayck, CP; Wagena, EJ, 2001) |
| "Therefore, smoking cessation is the most important therapeutic approach." | 2.40 | [Etiology, diagnosis and therapy of COPD]. ( Perruchoud, AP; Solèr, M; Ullmer, E, 1999) |
| "Despite increased awareness, COPD remains underdiagnosed." | 1.36 | [Update on current care guidelines: Chronic obstructive pulmonary disease, diagnosis and treatment]. ( , 2010) |
| "Theophylline has a lower efficacy/tolerance ratio than inhaled bronchodilators." | 1.35 | [Pharmacological treatment of stable chronic obstructive pulmonary disease]. ( Allain, YM; Giraud, F; Huchon, G; Roche, N, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (15.38) | 18.2507 |
| 2000's | 18 (69.23) | 29.6817 |
| 2010's | 4 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chui, CY | 1 |
| Taylor, SE | 1 |
| Thomas, D | 1 |
| George, J | 1 |
| Allain, YM | 1 |
| Giraud, F | 1 |
| Huchon, G | 1 |
| Roche, N | 1 |
| Cosio, BG | 1 |
| Soriano, JB | 1 |
| Worth, H | 1 |
| Gillissen, A | 1 |
| Altose, MD | 1 |
| Wepner, U | 1 |
| Green, RH | 1 |
| Brightling, CE | 1 |
| Pavord, ID | 1 |
| Wardlaw, AJ | 1 |
| Sin, DD | 1 |
| McAlister, FA | 1 |
| Man, SF | 1 |
| Anthonisen, NR | 1 |
| Toyoshima, H | 1 |
| Yoshida, M | 2 |
| Kino, H | 1 |
| Watz, H | 1 |
| Bitter-Suermann, S | 1 |
| Kanniess, F | 1 |
| Magnussen, H | 1 |
| Hamm, H | 1 |
| Kerstjens, H | 1 |
| Postma, D | 1 |
| ten Hacken, N | 1 |
| Nafti, S | 1 |
| Montuschi, P | 1 |
| Friedman, M | 1 |
| Ullmer, E | 1 |
| Solèr, M | 1 |
| Perruchoud, AP | 1 |
| Ishibasi, M | 1 |
| Nishida, T | 1 |
| Leckie, MJ | 1 |
| Bryan, SA | 1 |
| Hansel, TT | 1 |
| Barnes, PJ | 1 |
| Woodside, JR | 1 |
| Sherk, PA | 1 |
| Grossman, RF | 1 |
| Wagena, EJ | 1 |
| de Graaf, L | 1 |
| Chavannes, NH | 1 |
| van Grootheest, AC | 1 |
| van Schayck, CP | 1 |
| Listello, D | 1 |
| Glauser, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Implementation and Outcomes Evaluation of Blood-Based Biomarkers for COPD Management: COPD Prednisone Sub-Study[NCT02534402] | Phase 4 | 40 participants (Actual) | Interventional | 2015-08-31 | Active, not recruiting | ||
| Clinical Implementation and Outcomes Evaluation of Blood-Based Biomarkers for Chronic Obstructive Pulmonary Disease Management[NCT02050022] | 522 participants (Actual) | Observational | 2013-04-30 | Active, not recruiting | |||
| Effect of a Multimodal Pain Regimen on Pain Control, Patient Satisfaction and Narcotic Use in Orthopaedic Trauma Patients[NCT02160301] | Phase 4 | 0 participants (Actual) | Interventional | 2017-11-30 | Withdrawn (stopped due to Insufficient infrastructure/funding for enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
17 reviews available for theophylline and Smoking Cessation
| Article | Year |
|---|---|
[Bronchial asthma in pregnant women].
Topics: Administration, Oral; Adrenal Cortex Hormones; Adrenergic Agonists; Asthma; Bronchodilator Agents; F | 2010 |
Drugs for chronic obstructive pulmonary disease.
Topics: Adrenal Cortex Hormones; Bronchodilator Agents; Drug Therapy, Combination; Humans; Immunization; Neb | 2010 |
Approaches to slowing the progression of COPD.
Topics: Adrenal Cortex Hormones; Bronchodilator Agents; Cholinesterase Inhibitors; Clinical Trials as Topic; | 2003 |
Management of asthma in adults: current therapy and future directions.
Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Antagonists; Allergens; Anti-Asthmatic Agents; A | 2003 |
Contemporary management of chronic obstructive pulmonary disease: scientific review.
Topics: Adrenergic beta-Agonists; Bronchodilator Agents; Cholinergic Antagonists; Glucocorticoids; Humans; I | 2003 |
Contemporary management of chronic obstructive pulmonary disease: scientific review.
Topics: Adrenergic beta-Agonists; Bronchodilator Agents; Cholinergic Antagonists; Glucocorticoids; Humans; I | 2003 |
Contemporary management of chronic obstructive pulmonary disease: scientific review.
Topics: Adrenergic beta-Agonists; Bronchodilator Agents; Cholinergic Antagonists; Glucocorticoids; Humans; I | 2003 |
Contemporary management of chronic obstructive pulmonary disease: scientific review.
Topics: Adrenergic beta-Agonists; Bronchodilator Agents; Cholinergic Antagonists; Glucocorticoids; Humans; I | 2003 |
[Management of patients with stable COPD].
Topics: Adrenergic beta-Agonists; Bronchodilator Agents; Cholinergic Antagonists; Humans; Lung Transplantati | 2003 |
[New drug therapy of chronic obstructive pulmonary disease].
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Antidepressive Agents | 2003 |
[Pharmacological treatment of COPD and future of anti-inflammatory therapy].
Topics: Acetylcysteine; Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Anti- | 2006 |
[Stage appropriate therapy for COPD].
Topics: Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adrenergic beta-2 Recepto | 2006 |
Chronic obstructive pulmonary disease.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Anti-Bacterial Agents; Bronchodilator Agents; Cho | 2006 |
Pharmacological treatment of chronic obstructive pulmonary disease.
Topics: Adrenergic beta-Agonists; Anti-Infective Agents; Cholinergic Antagonists; Drug Therapy, Combination; | 2006 |
[Etiology, diagnosis and therapy of COPD].
Topics: Administration, Inhalation; Anti-Inflammatory Agents; Bronchodilator Agents; Humans; Lung Diseases, | 1999 |
[Pathophysiology and management of pulmonary emphysema].
Topics: Adrenergic beta-Agonists; Anti-Inflammatory Agents; Bronchodilator Agents; Cholinergic Antagonists; | 1999 |
Novel therapy for COPD.
Topics: Adrenergic beta-Agonists; Animals; Anti-Bacterial Agents; Antioxidants; Bronchodilator Agents; Chemo | 2000 |
The chronic obstructive pulmonary disease exacerbation.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Bacterial Infections; Bronchodilator Agents; Dietary | 2000 |
[Uneasiness about the safety of bupropion as an aid to smoking cessation unjustified ].
Topics: Adverse Drug Reaction Reporting Systems; Anticonvulsants; Antidepressive Agents; Antidepressive Agen | 2001 |
COPD: primary care management with drug and oxygen therapies.
Topics: Aged; Anti-Bacterial Agents; Bronchodilator Agents; Clinical Protocols; Geriatrics; Humans; Lung Dis | 1992 |
9 other studies available for theophylline and Smoking Cessation
| Article | Year |
|---|---|
Prevalence and recognition of highly significant medication-smoking cessation interactions in a smoke-free hospital.
Topics: Adult; Aged; Australia; Clozapine; Cross-Sectional Studies; Delivery of Health Care; Drug-Related Si | 2019 |
[Pharmacological treatment of stable chronic obstructive pulmonary disease].
Topics: Bronchodilator Agents; Drug Tolerance; Dyspnea; Exercise Test; Exercise Tolerance; Forced Expiratory | 2009 |
Theophylline again? Reasons for believing.
Topics: Anti-Inflammatory Agents; Aspirin; Asthma; Bronchodilator Agents; Humans; Inflammation; Phosphoric D | 2009 |
[Update on current care guidelines: Chronic obstructive pulmonary disease, diagnosis and treatment].
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Anti-Bacterial Agents; Bronchodilator Agents; | 2010 |
[The new COPD guidelines reviewed. Smoking cessation--and what else?].
Topics: Bronchodilator Agents; Cholinergic Antagonists; Forced Expiratory Volume; Glucocorticoids; Humans; P | 2003 |
[COPD treatment by drugs].
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Bronchodilator Agents; Cholinergic Antagonists | 2006 |
Changing practices in COPD. A new pharmacologic treatment algorithm.
Topics: Administration, Inhalation; Albuterol; Algorithms; Bronchodilator Agents; Drug Administration Schedu | 1995 |
Female smokers have increased postoperative narcotic requirements.
Topics: Adult; Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Gynecologic Surgical Procedures | 2000 |
[When cowboys are short of air. Alarm signs overlooked].
Topics: Adrenergic beta-Agonists; Cholinergic Antagonists; Dyspnea; Humans; Pulmonary Disease, Chronic Obstr | 2001 |